Gilead Sciences GILD Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $8.51B+1,673% | $480M-91.4% | $5.61B+22.9% | $4.57B-26.4% | ||
| $894M+7.1% | $835M+9.0% | $766M+20.3% | $637M+0.3% | ||
| —— | -$1.84B-91.7% | -$962M+38.0% | -$1.55B-1,238% | ||
| —— | -$139M— | —— | $406M— | ||
| $1.04B+143% | $426M-49.4% | $842M+172% | $310M+2,918% | ||
| —— | —— | -$347M-254% | $226M— | ||
| —— | $108M-76.4% | $458M— | —— | ||
| -$2.11B— | —— | -$1.77B— | —— | ||
| $10.02B-7.5% | $10.83B+35.2% | $8.01B-11.8% | $9.07B-20.3% | ||
| $563M+7.6% | $523M-10.6% | $585M-19.6% | $728M+25.7% | ||
| $1.07B-77.9% | $4.84B+320% | $1.15B-35.9% | $1.8B+13.4% | ||
| $3.65B— | —— | $1.93B+9.0% | $1.77B-49.7% | ||
| -$4.79B-39.0% | -$3.45B-52.3% | -$2.27B+8.2% | -$2.47B+21.2% | ||
| $4B+2.2% | $3.92B+2.9% | $3.81B+2.7% | $3.71B+2.9% | ||
| $1.92B+67.1% | $1.15B+15.0% | $1B-28.4% | $1.4B+156% | ||
| $408M-3.3% | $422M+81.9% | $232M-24.9% | $309M+82.8% | ||
| -$7.75B— | —— | -$5.13B+20.8% | -$6.47B+27.1% | ||
| $97M+343% | -$40M— | —— | —— | ||
| —— | $3.91B+480% | $673M+809% | $74M— | ||
| $2.39B+0.2% | $2.39B+2.0% | $2.34B+31.4% | $1.78B+3.4% | ||
| $370M-2.9% | $381M+7.6% | $354M+9.6% | $323M-1.8% | ||
| $311M+20.1% | $259M— | —— | $146M— | ||
| -$480M-36.0% | -$353M+57.3% | -$826M-5.9% | -$780M-30.7% | ||
| $1.02B-78.1% | $4.67B+305% | $1.16B+22.4% | $944M+0.5% | ||
| —— | -$58M-5,900% | $1M— | —— | ||
| $133M-73.0% | $492M+11.3% | $442M+157% | $172M-54.7% | ||
| $55M— | —— | $1.33B-16.1% | $1.59B-27.1% | ||
| $854M— | —— | $510M+23.8% | $412M-43.6% | ||
| -$440M-56.6% | -$281M-0.7% | -$279M-61.3% | -$173M-19.3% | ||
| $1.79B-9.2% | $1.97B-12.4% | $2.25B— | —— | ||
| $9.46B-8.2% | $10.31B+38.9% | $7.42B-11.1% | $8.34B-22.8% | ||
| $9.46B-8.2% | $10.31B+38.9% | $7.42B-11.1% | $8.34B-22.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $576.0M of capital expenditures, Gilead Sciences's free cash flow was $10.2B over the trailing twelve months, up 3.9% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
